



HAL
open science

Mycoviruses: future therapeutic agents of invasive fungal infections in humans?

W. W. J. Sande, J. R. Lo-Ten-Foe, A. Belkum, M. G. Netea, B. J. Kullberg,
A. G. Vonk

► **To cite this version:**

W. W. J. Sande, J. R. Lo-Ten-Foe, A. Belkum, M. G. Netea, B. J. Kullberg, et al.. Mycoviruses: future therapeutic agents of invasive fungal infections in humans?. *European Journal of Clinical Microbiology and Infectious Diseases*, 2010, 29 (7), pp.755-763. 10.1007/s10096-010-0946-7 . hal-00589767

HAL Id: hal-00589767

<https://hal.science/hal-00589767v1>

Submitted on 2 May 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Mycoviruses: future therapeutic agents of invasive fungal infections in humans?

W. W. J. van de Sande · J. R. Lo-Ten-Foe ·
A. van Belkum · M. G. Netea · B. J. Kullberg ·
A. G. Vonk

Received: 28 March 2010 / Accepted: 12 April 2010 / Published online: 2 May 2010
© Springer-Verlag 2010

Abstract Invasive fungal infections are relatively common opportunistic infections in immunocompromised patients and are still associated with a high mortality rate. Furthermore, these infections are often complicated by resistance or refractoriness to current antimicrobial agents. Therefore, an urgent need exists for new therapeutic strategies based on the identification of new microbial targets and novel antimicrobial agents. One such hypothetical therapeutic strategy may involve the use of mycoviruses that are able to selectively infect fungi. Current knowledge of mycoviruses of human pathogenic fungi and the scope for using (recombinant) mycoviruses as future biological control agents are reviewed here.

Introduction

Fungal infections such as invasive candidiasis and aspergillosis cause a high morbidity and mortality in immunocompromised patients. Although timely administration of

antifungal therapy has a significantly positive influence on the outcome of infection in such patients, treatment failure remains a major problem [1, 2]. As well as pivotal development of adjunctive immunotherapy to enforce antifungal host immune response, new therapeutic strategies are needed to selectively combat aspergillosis and other invasive opportunistic fungal diseases.

Mycoviruses are viruses that selectively infect fungi. Although the first reports on mycoviruses date from the 1960s [3], our knowledge and understanding of mycoviruses is still in its infancy. Moreover, current mycovirus publications primarily concern economically important fungi such as cultivated mushrooms, yeasts, and fungal pathogens of plants. To our knowledge, the use of mycoviruses as a tool to combat invasive fungal infection in animals and humans has not yet been suggested, let alone explored in any detail.

Mycovirus biology and interaction with the fungal host

The genetic information of mycoviruses is either encoded by double-stranded RNA (dsRNA), single-stranded RNA with or without a reverse transcription step for replication (ss(+)RNA-RT), or double-stranded DNA (dsDNA) [4]. The 8th report on virus taxonomy of the International Committee for Taxonomy of Viruses (ICTV) lists more than 90 mycoviruses covering 10 viral families [5]. A complete list of mycoviruses of plant pathogenic fungi can be found in a recent review by Pearson et al. [4]. Despite the limited data on mycoviruses of human pathogenic fungi, evidence is provided that mycoviruses do exist in various fungal genera that are pathogenic to humans [6–18]. The mycoviruses that are associated with fungal genera that can cause human fungal disease and are also formally known by the ICTV are listed in Table 1. In addition, viral

W. W. J. van de Sande · A. van Belkum · A. G. Vonk (✉)
Department of Medical Microbiology and Infectious Diseases,
Erasmus MC, University Medical Center Rotterdam,
s-Gravendijkwal 230,
3015 CE Rotterdam, The Netherlands
e-mail: a.vonk@erasmusmc.nl

J. R. Lo-Ten-Foe
Department of Medical Microbiology,
University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands

M. G. Netea · B. J. Kullberg
Department of Medicine, Radboud University Nijmegen Medical
Center, and Nijmegen Institute for Infection, Inflammation and
Immunity (N4i),
Nijmegen, The Netherlands

Table 1 List of mycoviruses of fungal genera known to be pathogenic to humans formally named and recognised by the ICTV

Genome	Family	Genus	Genus characteristics	Species	Genbank
<i>ss(+)/RNA</i>	<i>Narnaviridae</i>	<i>Narnavirus</i>	not segmented, nucleoprotein complex, not encapsidated	<i>Saccharomyces 20S RNA narnavirus</i> <i>Saccharomyces 23S RNA narnavirus</i>	AF039063 U90136
<i>ss(+)/RNA-RT</i>	<i>Pseudoviridae</i>	<i>Hemivirus</i>	50 nm, not segmented, not enveloped	<i>Candida albicans Tca2 virus</i> <i>Candida albicans Tca5 virus</i>	AF050215 AF065434
		<i>Pseudovirus</i>	30–40 nm, not segmented, not enveloped	<i>Saccharomyces paradoxus Ty5 virus</i> <i>Saccharomyces cerevisiae Ty1 virus</i> <i>Saccharomyces cerevisiae Ty2 virus</i> <i>Saccharomyces cerevisiae Ty4 virus</i>	U19263 M18706 M19542 X67284
	<i>Metaviridae</i>	<i>Metavirus</i>	50 nm, not segmented, not enveloped	<i>Cladosporium fulvum T-1 virus</i> <i>Fusarium oxysporum Skippy virus</i> <i>Saccharomyces cerevisiae Ty3 virus</i>	Z11866 L34658 M34549
<i>dsRNA</i>	<i>Chrysoviridae</i>	<i>Chrysovirus</i>	30–35 nm, segmented, not enveloped, multiple components	<i>Penicillium brevicopactus virus</i> <i>Penicillium chrysogenum virus</i> <i>Penicillium cyaneo-fulvum virus</i>	AF296439–42
	<i>Hypoviridae</i>	<i>Hypovirus</i>	-	<i>Aspergillus ochraceous virus</i>	
	<i>Partitiviridae</i>	<i>Partitivirus</i>	30–40 nm, segmented, not enveloped, multiple components	<i>Fusarium poae virus</i> <i>Fusarium solani virus 1</i> <i>Penicillium stoloniferum virus S</i> <i>Penicillium stoloniferum virus F</i>	AF015924 AF047013 D55688–9
	<i>Reoviridae</i>	<i>Mycoreovirus</i>	-	<i>Saccharomyces cerevisiae virus L-A(L1)</i>	J04692 X13426
	<i>Totiviridae</i>	<i>Totivirus</i>	40–43 nm, not segmented, not enveloped	<i>Saccharomyces cerevisiae virus L-BC(La)</i> <i>Aspergillus foetidus virus S</i> <i>Aspergillus niger virus S</i>	U01060
	Unassigned		Sub-viral RNA encoding killer toxins and requires co-infection with helper virus for productive multiplication	M satelites of <i>Saccharomyces cerevisiae virus L-A</i>	
	Unassigned			<i>Aspergillus foetidus virus F</i>	
	Unassigned			<i>Fusarium graminearum virus DK21</i>	

Confirmed species in italics; tentative and unassigned mycoviruses in regular font.

Data are extracted from Fauquet et al. [5] and from *ICTVdB-The Universal Virus Database*, version 4. <http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/>.

particles have also been detected in *Alternaria alternata*, *Rhizopus* and *Mucor* spp., *Candida albicans*, *C. tropicalis*, *C. lipolytica* and *C. curvata*, but these fungal genera are omitted from Table 1 because they are not listed in the ICTV report [11–14, 16, 18].

To date, the majority of characterised mycoviruses of pathogenic fungi have dsRNA genomes. These viruses have subsequently been grouped into five families: *Partitiviridae*, *Totiviridae*, *Chrysoviridae*, *Reoviridae*, and *Hypoviridae* [5]. The families mainly differ in the number of genome segments and the way they are packaged. An almost universal trait of the dsRNA mycoviruses is the presence of capsids (except for *Hypoviridae*), which are selectively porous protein compartments in which the genome and replicase are contained. Nucleotides diffuse into this compartment and nascent positive sense strands are extruded from it. DsRNA mycoviruses are not surrounded by an envelope. A synopsis of the dsRNA viruses and their characteristics relevant to human pathogenic fungi is provided in Fig. 1.

Transmission of mycoviruses

Intracellular transmission

Mycoviruses are mainly spread by vertical transmission through asexual or sexual spore formation, with asexual sporulation being the most efficient means of transmission. Transmission also occurs horizontally via cytoplasmic exchange during cell division and mating with strains that, depending on the genus, do not have to be genetically compatible for virus transfer to occur [9, 19–22]. As a rule, however, when two fusing hyphae are not compatible, they

recognize each other as nonself, which triggers programmed cell death (PCD). In aspergilli, the genes involved in activation of PCD reactions are currently being characterised and regarded as a promising approach to combat invasive aspergillosis [23–26]. Genetic incompatibility is mostly followed by death of the hyphal fusion cell, the so-called heterokaryon, and often of surrounding cells. When this occurs, transmission of mycoviruses fails (Fig. 2). Rejection of heterokaryon formation has been observed to be relatively mild or absent when hyphae of less related *Aspergillus* species fuse [9].

Direct transmission of mycoviruses from one fungal species to another occurred following another experimental means, namely, induced fusion of cell wall-free fungi, so-called protoplasts. Using protoplast fusion, mycoviruses may even be transferred between two fungal compartments of strains that are heterokaryon incompatible [9].

Extracellular transmission

Bearing in mind that crossing the cellular membrane is a key step in the infectious life cycle of all viruses, it is understandable that the rigid cell wall in fungi serves as a membrane shielding structure constituting a barrier to extracellular virus uptake. For instance, dsRNA mycoviruses with an average size of 40 nm are approximately nine times the pore-size of the cell wall matrix in *Candida* species [27]. The cell wall thus prevents the virus from reaching the cell membrane to gain entry. Consequently, mycoviruses are unable to initiate fungal infections by extracellular routes. However, whereas the understanding of (enveloped) virus entry via membrane fusion is well advanced for mammalian viruses or viruses that selectively







	Hypoviridae	Totiviridae	Partitiviridae	Chrysoviridae	Reoviridae
genome:	monopartite	monopartite	bipartite	tertrapartite	mutisegmented
number of capsids:	 unencapsidated membrane vesicle	 IMNV, tentative totivirus			
associated hypovirulence:	yes	yes	no	yes	yes
host:	fungi	fungi protozoa	fungi plants	fungi	fungi plants protozoa vertebrates

Fig. 1 List of the predominating genome type of the dsRNA mycoviruses. Taxonomic families that are associated with pathogenic fungi are shown with the genome composition, virus structure, associated hypovirulence, as well as the host range of the respective viral families

Fig. 2 Transfer of mycoviruses between fungal hyphae is dependent on the compatibility of the donor and acceptor hyphae upon contact



infect bacteria (bacteriophages), the entry mechanisms for non-enveloped viruses, virus-like particles or naked virus-like dsRNA are still in infancy. Therefore, it may well be that the overall routes and mechanisms of extracellular virus transfer still remain to be elucidated. Infection by the extracellular route could thus far only be achieved in special experimental settings using protoplasts. Applying this method, purified viral particles belonging to the dsRNA families of *Partitiviridae*, *Totiviridae*, and *Reoviridae* successfully infected fungal protoplasts [10, 28, 29].

Experimental introduction of genetic information

Fungi have been transfected using an infectious complementary DNA (cDNA) copy of mycovirus RNA [30]. Transfected fungi showed cytoplasmically replicating dsRNA, demonstrating that a synthetic transcript corresponding to the coding strand of mycovirus dsRNA can initiate an infection when introduced into fungal protoplasts [30]. Again, this has putative therapeutic implications.

Mycelial spread of mycoviruses after transmission

In septate fungi, hyphal compartments are interconnected through hyphal pores. Replicating mycoviruses are thus able to spread throughout the colony via plasma streaming [28, 30] (Fig. 2). If the spread of mycoviruses throughout the colony occurs mainly via plasma streaming and not via fusion with neighbouring hyphae, the viral replication rate may be the limiting factor of transmission. Even after successful mycovirus transmission, persistence may not be obtained. This may be the case when compatible hyphae that form a heterokaryon are both infected with a different mycovirus. Co-infections may be generated, but the mycovirus in the acceptor fungus may also be replaced by the mycovirus from the donor. Indeed, viruses are not

always detected in the colonies derived from the protoplast/hyphae fusion products [9]. This suggests that mycoviruses can be selectively eliminated upon regeneration and outgrowth of (transfected) protoplasts as a result of intra-host competition between viruses.

Symptoms associated with mycovirus infection

Generally, mycoviruses cause latent and persistent infections [31]. Some mycovirus families are connected with variable phenotypic effects such as hypovirulence or killer phenomena in their host. Hypovirulence is, among other characteristics, defined as reduced pigmentation, reduced asexual sporulation, loss of fertility, or reduced growth rate. Hypovirulence-associated mycoviruses have ssRNA or, mainly, dsRNA genomes (Fig. 1) [8, 32–35]. The killer phenomena are induced by proteins encoded by satellite dsRNA that are associated with *Totiviruses* (discussed below) [36].

Isolation of mycoviruses and maintenance

Once fungi are successfully transfected, the observed infection patterns are very stable when subcultured [9, 28]. Furthermore, viruses present in *Aspergillus* isolates are highly efficiently transmitted to asexual progeny [21].

Limited data exist regarding the amount of mycoviruses that can be isolated from infected fungi and their stability after isolation. Most viruses have only been isolated with a relatively low yield. Hillman et al. showed that 3–6 µg of purified reovirus was obtained from each purification reaction, representing 2 l of infected fungi. These isolated *Reoviridae* were quite stable and retained infectivity upon prolonged storage [29]. In contrast, *Saccharomyces cerevisiae* *Totivirus* preparations stored refrigerated for three weeks became non-infectious [10]. Thus, isolation, production, purity and stability of mycoviruses of interest remain to be assessed.

Mycoviruses and toxins

As stated above, some mycovirus infections have a toxin-mediated killing capacity. Although a filamentous basidiomycete fungus, *Ustilago maydis*, is known to secrete killer toxins encoded by cytoplasmic dsRNA mycoviruses that are lethal to mycovirus-free susceptible strains of the same fungus [37–39], most killer phenotypes and their applications characterized to date are derived from yeasts. Killer yeasts are immune to their own secreted toxins, while remaining susceptible to others. Toxin-coding cytoplasmic dsRNA-mycoviruses have been detected in *Saccharomyces cerevisiae* and in non-conventional yeasts such as *Hanseniaspora uvarum* and *Zygosaccharomyces bailii* [10, 40]. In contrast to the *S. cerevisiae* toxins, killer toxins of non-*Saccharomyces* yeasts and especially those secreted by virus-infected killer strains of the yeasts *H. uvarum* and *Z. bailii* show a broad-spectrum antimycotic potential to human pathogenic strains, such as *Candida albicans*, *Sporothrix schenckii*, and *Fusarium* sp. [36, 41]. The toxin isolated from *Z. bailii*, zygocin, effectively kills *C. albicans*, *C. glabrata* and *C. tropicalis* yeast cells and germlings. Moreover, on a molar basis, zygocin is even more effective in killing yeasts than antifungal agents such as clotrimazole or miconazole, suggesting that zygocin is a promising antifungal agent [42].

The outer cell wall layer of yeasts predominantly consist of mannoproteins, connected to a glucan skeleton consisting of linear and branched beta-1,3- and beta-1,6-D-glucans, and to a much lesser extent of chitin which mainly concentrates in bud scars [43]. In the search for novel and more selective antifungal agents, fungal cell wall components represent primary targets, as these structures are restricted to yeasts and higher fungi and do not occur in human cells [44, 45]. Each of the mentioned cell wall components has been shown to act as the primary binding site for different yeast killer toxins [46–49]. In addition, for killer toxins secreted by various strains of the yeast *Hansenula* it was demonstrated that these toxins not only bind to yeast cell wall components, but that they also strongly inhibit de novo L-1,3-D-glucan biosynthesis [50, 51]. Given the cell wall related activity of mycovirus-encoded killer toxins, antifungal research has indeed focused on the possible use of yeast killer toxins as novel antifungal agents for the treatment of fungal infections [52]. Clinical recovery as well as negative mycological test cultures of experimental dermatomycosis in animals proved to be clearly associated with topical killer toxin treatment [53]. However, although some researchers have shown that topical applications in the treatment of superficial lesions might well be possible, one drawback of most yeast killer proteins is that they exhibit their cytotoxic activity only at temperatures between 20°C and 30°C within a narrow pH range [53, 54]. Therefore, yeast toxins are unsuitable as

direct applications for oral and/or intravenous administration [55]. Killer toxins, however, fuelled the development of new antifungal agents that mimic the antimicrobial activity of killer toxins, so-called killer antibodies and killer antibody-derived peptides. These derivatives have shown activity against various human fungal pathogenic fungi including *C. albicans* and may be therapeutic when administered parentally. For reviews of killer toxin/antibodies the reader is referred to Marquina et al. [49], Magliani et al. [55], and Schmitt and Breinig [40].

Viruses as therapeutic agents for infections in humans

The idea to cure infections in humans with viruses as biological control agents is not new. Most research has been conducted using viruses that specifically and uniquely search and destroy bacteria. These bacteriophages—‘eaters of bacteria’—have been known since the early 20th century [56]. To offer support for the contention that a strategy using mycoviruses in the treatment of medically important fungi can be effective, analogous research using bacteriophages for treating bacterial infections is briefly reviewed.

Bacteriophages are ubiquitous and found in many different environments including soil, human and animal bodies; they do not attack human cells and exist as partners in microbiological eco-systems in mammals. Bacteriophages may be divided into a number of basic types based on morphological and genome analysis. The genome types are dsDNA, ssDNA, dsRNA and ssRNA. The most prevalent bacteriophages are tailed and all tailed bacteriophages have dsDNA. Furthermore, these tail fibres confer host specificity within this group [5].

Although a large number of publications have suggested that bacteriophages may be effective therapeutic agents in clinical settings, most published studies are uncontrolled or anecdotal and do not meet the criteria of modern evidence [56]. However, recently, proof of principle has been provided as bacteriophage therapies have been developed for multiresistant bacteria and other difficult to treat infections [57, 58]. For instance, it has been shown that a bacteriophage with lytic activity against vancomycin resistant *Enterococcus faecium* (VRE) successfully cured mice from VRE bacteraemia [59]. A review of various experimental infections treated with bacteriophages can be found in the work of O’Flaherty et al. [60]. In addition, the therapeutic bacteriophage of VRE bacteraemia was well tolerated in a phase I clinical trial [57]. Other clinical trials have shown that bacteriophages could be safely administered, even to children, and demonstrated cost effectiveness over antibiotic treatment of infections caused by multidrug-resistant bacteria [61, 62]. Furthermore, the first results of a randomised, double-

blind, placebo-controlled phase I/II clinical trial of a bacteriophage therapeutic targeting long-term ear infections with *P. aeruginosa* refractory to antibiotic showed both efficacy and safety [63].

In tandem with the resurgent interest in bacteriophages as therapeutic agents and the advent of high throughput sequencing, the number of bacteriophage genomes sequenced to completion has drastically increased to >500 [60]. Although host species specificity is the rule for most bacteriophages investigated, many bacteriophages have developed efficient methods to change their host range via genetic mechanisms [64]. The dsDNA *Escherichia coli* bacteriophage, Phi K1-5, for example, has shown to be capable of infecting *E. coli* strains that possess either the K1 or the K5 polysaccharide capsule due to possession of two different tail fiber proteins. The arrangement of genes suggests that this bacteriophage can broaden its host range by horizontal gene transfer [65].

Although bacteriophages have a unique and limited bactericidal spectrum, they are almost as numerous as bacteria and the development of therapeutic bacteriophages is therefore hardly problematic. Furthermore, nowadays, engineering of genes involved in host recognition may be an additional approach for generating an expanded host range.

Host range expansion using genetic engineering

Pyocins

Engineering of genes involved in host recognition results in host range expansion. Evidence is mostly provided by the studies of R-type pyocins. Certain *Pseudomonas aeruginosa* strains produce R-type pyocins (henceforth called pyocins), protein particles resembling non-flexible and contractile tails of bacteriophages [66]. Although many pyocin genes share common ancestry with bacteriophage genes, pyocins differ from bacteriophages, for they do not contain nucleic acid and cannot replicate. Both bacteriophages and pyocins bind to an accessible receptor on the target bacterium, but pyocins kill the target bacterium by a different mechanism. Pyocins kill bacteria by first binding to a cell surface structure via tail fibers, followed by contraction of the sheath and insertion of their hollow core through the cell envelope resulting in depolarization of the cytoplasmic membrane and cell death [67]. Pyocin has been shown to increase survival and reduce bacterial counts in a lethal murine experimental *Pseudomonas* peritonitis model [68]. The bactericidal specificity of pyocins is conferred by their tail fibers encoded by *prf15*. A chaperone, encoded by *prf16* immediately downstream of *prf15*, is required for tail fiber assembly [69]. Chimeric tail fusion fibers that bind to

presumably different bacterial surface molecules have been engineered. The generated chimeric tail fibers that formed active pyocins resulted from many trials of empirically chosen fusion sites between *prf15* and portions of bacteriophage tail/spike fibers. The engineered fusions between N-terminal portions of the pyocin tail fiber and various C-terminal portions of the bacteriophage tail/spike fibers resulted in pyocin host range expansion from *Pseudomonas* to *Yersinia* and various *E. coli* strains [70, 71]. Scholl et al. further envisage that an unlimited amount of chimeric pyocins can be created based on the presence of a vast number and diversity of bacteriophage tail fibres combined with the application of phage display techniques. This may provide even greater diversity of binding specificities than exists naturally on pyocins and could lead to an almost unlimited number of bactericidal agents.

Plant viruses

Similarly, plant viruses have been genetically modified to express heterologous proteins for vaccine development. To this purpose, coat protein genes of several plant viruses have been genetically altered to express foreign antigenic epitopes of human or animal origin as fusions to the viral coat protein. These foreign epitopes are exposed and displayed on the surface of chimeric virus particles [72]. Although the size of the peptide fusions that still permit virus assembly is limited [73], several strategies have been developed to overcome assembly problems for long or difficult peptides. These include “Foot and Mouth Disease Virus 2A peptide coat protein (CP) fusion strategy” and the so-called “leaky stop codon CP fusion strategy”, which would cause most of the CP produced to be unfused, while a small portion would be fused to the peptide displayed on the surface [74–76].

Fusion proteins have to be compatible with normal viral assembly and fitness, and steric hindrance or interference with virus movement must be avoided to sustain infection. Indeed, recombinant viruses expressing foreign antigenic peptides on their surface can remain infectious and retain the foreign sequences during passage from plant to plant [73, 76]. Many stable mutants have already been prepared that allow specific modification of the capsid surface of plant viruses (for a review, see [77]).

Mycoviruses

Likewise, in mycovirus research for vaccine development against aspergillosis, the transposon *Ty1* of yeast *Saccharomyces cerevisiae* has successfully been used for the expression of *Aspergillus* peptides on its surface. This bifunctional virus-like particle engineered to contain peptides representing dominant T- and B-cell epitopes of

Aspergillus proved more potent in stimulating memory immune responses [78].

One possible scenario that can be derived from the results of genetic modification of bacteriophages, pyocins, plant viruses, and mycoviruses described above, is the generation of a selective mycovirus that is transmitted extracellularly in an efficient way. Genetic modification of structures involved in mycovirus binding to the target fungus may be the first that comes to mind. To date, such a mycovirus is not known to exist. Recently however, the infectious myonecrosis virus (IMNV) was discovered as the cause of infectious myonecrosis in penaeid shrimp. IMNV is tentatively considered as a totivirus due to its RNA-dependent RNA-polymerase (RdRp) that matches significantly with the consensus sequence of the RdRp of the *Totiviridae* family [79]. As outlined above, totiviruses are able to infect fungi and have no known capacity to infect humans, and most totiviruses lack the means to be transmitted extracellularly. IMNV is an exception (Fig. 1) and therefore may be an interesting candidate for genetic engineering to expand its host range [80]. Similar to the surface fibers in other viruses, the IMNV protrusions are almost certainly involved in cell entry, including receptor binding and/or membrane penetration, i.e. confer host specificity. Exploring if genetic modification of IMNV protrusions generates a chimeric virus that is able to selectively infect fungi via an extracellular mode of transmission may be an interesting field of research.

Mycoviruses as gene vectors

Another possible scenario, apart from generating a chimeric mycovirus that is efficiently transmitted extracellularly, may be its use as a gene insertion vector. As such, the virus does not need to be detrimental to the fungus itself, as is the case for most mycoviruses in their natural life cycle, but the mycovirus should be able to function as a “Trojan horse”, expressing foreign inserts “upon request” (Table 2). This has already been applied in fighting fungal diseases in plants using killer toxins (discussed above) [81]. The gene encoding a broad spectrum yeast killer toxin was inserted in Potato virus X and yielded particles displaying an active form of the killer peptide against the plant pathogenic fungi of interest and, additionally, also displayed activity against *C. albicans* [81].

Of note, recombinant mycoviruses have to meet various criteria and characteristics. Research into the field of mycoviruses can only be performed in a model system that offers a high virus yield and is safe at the same time with the lowest risk possible of emergence of viruses capable of infecting humans. Characteristics required are summarised in Table 2.

Table 2 Ideal characteristics of mycoviruses intended to be used as biocontrol agents of invasive fungal infections in humans

The mycovirus should	The mycovirus should NOT
have an extracellular mode of transmission	be able to cause infection in the human host
replicate efficiently in fungi pathogenic to humans	be able to recombine with human pathogenic viruses
cause 100% lysis of the fungal target	be able to integrate into the human genome
have a broad anti-fungal range	induce (serious) side effects
readily be produced in large quantities with high purity and stability at low cost	induce production of neutralising antibodies
have topical and systemic applicability	
have a genome that facilitates genetic manipulation	
have modifiable levels of expression of foreign inserts when requested and the foreign inserts should not interfere with normal viral assembly and fitness and steric hindrance or interference with virus movement must be avoided	

Overcoming the cell wall barrier

As explained before, the fungal cell wall poses a barrier to viral entry. Different types of strategies can be hypothesized to overcome this obstacle. One such strategy may be pretreatment with an antifungal agent to induce holes in the fungal wall thus exposing the cell membrane surface to mycovirus application. Another strategy may be the use of delivery systems. Because dsRNA viruses are approximately 2.5 times smaller than empty Amphotericin B liposomes which measure 100 nm (Gilead Science), liposomes are an interesting delivery system. The delivery system, or the mycovirus itself, may be expressing enzymes that have chitinase or glucanase activity. Again, this idea was strengthened by observations from studying bacteriophages. Bacteria sometimes produce thick polysaccharide capsules for protection in hostile environments which also limits infection with bacteriophages. Some bacteriophages, however, express enzymes with capsule-depolymerizing activities. Bacteriophages expressing these enzymes that are attached via an adapter protein to the virus portal vertex through which the DNA is ejected during infection are able to digest their way through 400-nm thick capsules [82, 83].

Conclusion

In their natural life cycle, mycoviruses are usually non-transmissible by an extracellular route and cause persistent

infections in their host without phenotypic alterations. However, based on results obtained with chimeric plant viruses, bacteriophages and pyocins, genetic engineering of existing mycoviruses is possible. Mycovirus therapy may thus be regarded as an interesting and promising direction for future research and may provide an alternative therapeutic biological agent against invasive fungal infections.

References

- Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev* 20:133–163
- Slobbe L, Polinder S, Doorduijn JK et al (2008) Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. *Clin Infect Dis* 47:1507–1512
- Hollings M (2009) Viruses associated with a die-back disease of cultivated mushroom. *Nature* 196:962–965
- Pearson MN, Beever RE, Boine B, Arthur K (2009) Mycoviruses of filamentous fungi and their relevance to plant pathology. *Mol Plant Pathol* 10:115–128
- Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA eds (2005) *Virus taxonomy: eighth report of the International Committee on Taxonomy of Viruses*. Elsevier Academic Press, San Diego
- Bozarth RF (1972) Mycoviruses: a new dimension in microbiology. *Environ Health Perspect* 2:23–39
- Border DJ, Buck KW, Chain EB, Kempson-Jones GF, Lhoas P, Ratti G (1972) Viruses of *Penicillium* and *Aspergillus* species. *Biochem J* 127:4P–6P
- van Diepeningen AD, Debets AJ, Hoekstra RF (2006) Dynamics of dsRNA mycoviruses in black *Aspergillus* populations. *Fungal Genet Biol* 43:446–452
- van Diepeningen AD, Debets AJ, Hoekstra RF (1998) Intra- and interspecies virus transfer in Aspergilli via protoplast fusion. *Fungal Genet Biol* 25:171–180
- El-Sherbeini M, Bostian KA (1987) Viruses in fungi: infection of yeast with the K1 and K2 killer viruses. *Proc Natl Acad Sci U S A* 84:4293–4297
- Papp T, Nyilasi I, Fekete C, Ferenczy L, Vagvolgyi C (2001) Presence of double-stranded RNA and virus-like particles in *Rhizopus* isolates. *Can J Microbiol* 47:443–447
- Vagvolgyi C, Magyar K, Papp T et al (1998) Detection of double-stranded RNA molecules and virus-like particles in different *Mucor* species. *Antonie Leeuwenhoek* 73:207–210
- Mehta RJ, Nash CH 3rd, Bozzola JJ (1982) Virus-like particles and lytic plaque formation in lawns of *Candida albicans*. *J Bacteriol* 152:502–505
- Matte O, Chabaliere C, Ratomahenina R, Bossy JP, Galzy P (1990) Isolation and characterization of a RNA-virus like particle from *Candida curvata*. *Biol Cell* 68:159–162
- Hammond TM, Andrews MD, Roossinck MJ, Keller NP (2008) *Aspergillus* mycoviruses are targets and suppressors of RNA silencing. *Eukaryot Cell* 7:350–357
- Nesterova GF, Kierner I, Soom I (1973) Virus-like particles in *Candida tropicalis*. *Mikrobiologiya* 42:162–165
- El-Sherbeini M, Bostian KA, Levitre J, Mitchell DJ (1987) Gene-protein assignments within the yeast *Yarrowia lipolytica* dsRNA viral genome. *Curr Genet* 11:483–490
- Aoki N, Moriyama H, Kodama M, Arie T, Teraoka T, Fukuhara T (2009) A novel mycovirus associated with four double-stranded RNAs affects host fungal growth in *Alternaria alternata*. *Virus Res* 140:179–187
- Coenen A, Kevei F, Hoekstra RF (1997) Factors affecting the spread of double-stranded RNA viruses in *Aspergillus nidulans*. *Genet Res* 69:1–10
- Hillman BI, Suzuki N (2004) Viruses of the chestnut blight fungus, *Cryphonectria parasitica*. *Adv Virus Res* 63:423–472
- van Diepeningen AD, Debets AJ, Hoekstra RF (1997) Heterokaryon incompatibility blocks virus transfer among natural isolates of black Aspergilli. *Curr Genet* 32:209–217
- Liu YC, Linder-Basso D, Hillman BI, Kaneko S, Milgroom MG (2003) Evidence for interspecies transmission of viruses in natural populations of filamentous fungi in the genus *Cryphonectria*. *Mol Ecol* 12:1619–1628
- Fedorova ND, Badger JH, Robson GD, Wortman JR, Nierman WC (2005) Comparative analysis of programmed cell death pathways in filamentous fungi. *BMC Genomics* 6:177
- Davies JR, Osmani AH, De Souza CP, Bachewich C, Osmani SA (2004) Potential link between the NIMA mitotic kinase and nuclear membrane fission during mitotic exit in *Aspergillus nidulans*. *Eukaryot Cell* 3:1433–1444
- Fedorova ND, Khaldi N, Joardar VS et al (2008) Genomic islands in the pathogenic filamentous fungus *Aspergillus fumigatus*. *PLoS Genet* 4:e1000046
- van Diepeningen AD, Pal K, van der Lee TA, Hoekstra RF, Debets AJ (2009) The *het-c* heterokaryon incompatibility gene in *Aspergillus niger*. *Mycol Res* 113:222–229
- Yphantis DA, Dainko JL, Schlenk F (1967) Effect of some proteins on the yeast cell membrane. *J Bacteriol* 94:1509–1515
- Sasaki A, Kanematsu S, Onoue M, Oyama Y, Yoshida K (2006) Infection of *Rosellinia necatrix* with purified viral particles of a member of *Partitiviridae* (RnPV1-W8). *Arch Virol* 151:697–707
- Hillman BI, Supyani S, Kondo H, Suzuki N (2004) A reovirus of the fungus *Cryphonectria parasitica* that is infectious as particles and related to the coltivirus genus of animal pathogens. *J Virol* 78:892–898
- Chen B, Craven MG, Choi GH, Nuss DL (1994) cDNA-derived hypovirus RNA in transformed chestnut blight fungus is spliced and trimmed of vector nucleotides. *Virology* 202:441–448
- Buck KW (1986) Fungal virology—an overview. In: Buck KW (ed) *Fungal virology*. CRC Press, Florida, pp 1–84
- Polashock JJ, Bedker PJ, Hillman BI (1997) Movement of a small mitochondrial double-stranded RNA element of *Cryphonectria parasitica*: ascospore inheritance and implications for mitochondrial recombination. *Mol Gen Genet* 256:566–571
- Park SM, Choi ES, Kim MJ, Cha BJ, Yang MS, Kim DH (2004) Characterization of HOG1 homologue, *cpMK1*, from *Cryphonectria parasitica* and evidence for hypovirus-mediated perturbation of its phosphorylation in response to hypertonic stress. *Mol Microbiol* 51:1267–1277
- Deng F, Allen TD, Hillman BI, Nuss DL (2007) Comparative analysis of alterations in host phenotype and transcript accumulation following hypovirus and mycoreovirus infections of the chestnut blight fungus *Cryphonectria parasitica*. *Eukaryot Cell* 6:1286–1298
- Jiang D, Ghabrial SA (2004) Molecular characterization of *Penicillium chrysogenum* virus: reconsideration of the taxonomy of the genus *Chrysovirus*. *J Gen Virol* 85:2111–2121
- Schmitt MJ, Poravou O, Trenz K, Rehfeldt K (1997) Unique double-stranded RNAs responsible for the anti-*Candida* activity of the yeast *Hanseniaspora uvarum*. *J Virol* 71:8852–8855
- Park CM, Banerjee N, Koltin Y, Bruenn JA (1996) The *Ustilago maydis* virally encoded KP1 killer toxin. *Mol Microbiol* 20:957–963
- Gage MJ, Bruenn J, Fischer M, Sanders D, Smith TJ (2001) KP4 fungal toxin inhibits growth in *Ustilago maydis* by blocking calcium uptake. *Mol Microbiol* 41:775–785

39. Li N, Erman M, Pangborn W et al (1999) Structure of *Ustilago maydis* killer toxin KP6 alpha-subunit. A multimeric assembly with a central pore. *J Biol Chem* 274:20425–20431
40. Schmitt MJ, Breinig F (2002) The viral killer system in yeast: from molecular biology to application. *FEMS Microbiol Rev* 26:257–276
41. Hodgson VJ, Button D, Walker GM (1995) Anti-*Candida* activity of a novel killer toxin from the yeast *Williopsis mrakii*. *Microbiology* 141:2003–2012
42. Weiler F, Schmitt MJ (2003) Zygocin, a secreted antifungal toxin of the yeast *Zygosaccharomyces bailii*, and its effect on sensitive fungal cells. *FEMS Yeast Res* 3:69–76
43. Cabib E, Drgon T, Drgonova J, Ford RA, Kollar R (1997) The yeast cell wall, a dynamic structure engaged in growth and morphogenesis. *Biochem Soc Trans* 25:200–204
44. Kurtz MB (1998) New antifungal drug targets: a vision for the future. *ASM News* 64:31–39
45. Hector RF (1993) Compounds active against cell walls of medically important fungi. *Clin Microbiol Rev* 6:1–21
46. Schmitt M, Radler F (1987) Mannoprotein of the yeast cell wall as primary receptor for the killer toxin of *Saccharomyces cerevisiae* strain 28. *J Gen Microbiol* 133:3347–3354
47. Hutchins K, Bussey H (1983) Cell wall receptor for yeast killer toxin: involvement of (1 leads to 6)-beta-D-glucan. *J Bacteriol* 154:161–169
48. Jablonowski D, Fichtner L, Martin VJ et al (2001) *Saccharomyces cerevisiae* cell wall chitin, the *Kluyveromyces lactis* zymocin receptor. *Yeast* 18:1285–1299
49. Marquina D, Santos A, Peinado JM (2002) Biology of killer yeasts. *Int Microbiol* 5:65–71
50. Yamamoto T, Hiratani T, Hirata H, Imai M, Yamaguchi H (1986) Killer toxin from *Hansenula mrakii* selectively inhibits cell wall synthesis in a sensitive yeast. *FEBS Lett* 197:50–54
51. Kimura T, Kitamoto N, Kito Y et al (1997) A novel yeast gene, RHK1, is involved in the synthesis of the cell wall receptor for the HM-1 killer toxin that inhibits beta-1, 3-glucan synthesis. *Mol Gen Genet* 254:139–147
52. Selitrennikoff CP (2001) Antifungal proteins. *Appl Environ Microbiol* 67:2883–2894
53. Polonelli L, Lorenzini R, De BF, Morace G (1986) Potential therapeutic effect of yeast killer toxin. *Mycopathologia* 96:103–107
54. Walker GM, McLeod AH, Hodgson VJ (1995) Interactions between killer yeasts and pathogenic fungi. *FEMS Microbiol Lett* 127:213–222
55. Magliani W, Conti S, Travassos LR, Polonelli L (2008) From yeast killer toxins to antibiobodies and beyond. *FEMS Microbiol Lett* 288:1–8
56. Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. *Antimicrob Agents Chemother* 45:649–659
57. Stone R (2002) Bacteriophage therapy. Stalin's forgotten cure. *Science* 298:728–731
58. Bradbury J (2004) "My enemy's enemy is my friend." Using phages to fight bacteria. *Lancet* 363:624–625
59. Biswas B, Adhya S, Washart P et al (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant *Enterococcus faecium*. *Infect Immun* 70:204–210
60. O'Flaherty S, Ross RP, Coffey A (2009) Bacteriophage and their lysins for elimination of infectious bacteria. *FEMS Microbiol Rev* 33:801–819
61. Bruttin A, Brussow H (2005) Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother* 49:2874–2878
62. Fortuna W, Miedzybrodzki R, Weber-Dabrowska B, Gorski A (2008) Bacteriophage therapy in children: facts and prospects. *Med Sci Monit* 14:RA126–RA132
63. Wright A, Hawkins CH, Anggard EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin Otolaryngol* 34:349–357
64. Chibani-Chennoufi S, Bruttin A, Dillmann ML, Brussow H (2004) Phage-host interaction: an ecological perspective. *J Bacteriol* 186:3677–3686
65. Scholl D, Rogers S, Adhya S, Merrill CR (2001) Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of *Escherichia coli*. *J Virol* 75:2509–2515
66. Michel-Briand Y, Baysse C (2002) The pyocins of *Pseudomonas aeruginosa*. *Biochimie* 84:499–510
67. Uratani Y, Hoshino T (1984) Pyocin R1 inhibits active transport in *Pseudomonas aeruginosa* and depolarizes membrane potential. *J Bacteriol* 157:632–636
68. Scholl D, Martin DW Jr (2008) Antibacterial efficacy of R-type pyocins towards *Pseudomonas aeruginosa* in a murine peritonitis model. *Antimicrob Agents Chemother* 52:1647–1652
69. Nakayama K, Takashima K, Ishihara H et al (2000) The R-type pyocin of *Pseudomonas aeruginosa* is related to P2 phage, and the F-type is related to lambda phage. *Mol Microbiol* 38:213–231
70. Williams SR, Gebhart D, Martin DW Jr, Scholl D (2008) Retargeting R-type pyocins to generate novel bactericidal protein complexes. *Appl Environ Microbiol* 74:3868–3876
71. Scholl D, Cooley M, Williams SR et al (2009) An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen *Escherichia coli* O157:H7. *Antimicrob Agents Chemother* 53:3074–3080
72. Johnson J, Lin T, Lomonosoff G (1997) Presentation of heterologous peptides on plant viruses: genetics, structure, and function. *Annu Rev Phytopathol* 35:67–86
73. Yusibov V, Modelska A, Steplewski K et al (1997) Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. *Proc Natl Acad Sci USA* 94:5784–5788
74. de Felipe P, Hughes LE, Ryan MD, Brown JD (2003) Co-translational, intraribosomal cleavage of polypeptides by the *Foot-and-mouth disease virus* 2A peptide. *J Biol Chem* 278:11441–11448
75. Borovsky D, Rabindran S, Dawson WO et al (2006) Expression of *Aedes trypsin*-modulating oostatic factor on the virion of TMV: a potential larvicide. *Proc Natl Acad Sci USA* 103:18963–18968
76. Cruz SS, Chapman S, Roberts AG, Roberts IM, Prior DA, Oparka KJ (1996) Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. *Proc Natl Acad Sci USA* 93:6286–6290
77. Lico C, Chen Q, Santi L (2008) Viral vectors for production of recombinant proteins in plants. *J Cell Physiol* 216:366–377
78. Marchenko AN, Kozlov DG, Svirshchevskaya EV, Viskova NY, Benevolensky SV (2003) The p1 protein of the yeast transposon *Ty1* can be used for the construction of bi-functional virus-like particles. *J Mol Microbiol Biotechnol* 5:97–104
79. Poulos BT, Tang KF, Pantoja CR, Bonami JR, Lightner DV (2006) Purification and characterization of infectious myonecrosis virus of penaeid shrimp. *J Gen Virol* 87:987–996
80. Tang J, Ochoa WF, Sinkovits RS et al (2008) Infectious myonecrosis virus has a totivirus-like, 120-subunit capsid, but with fiber complexes at the fivefold axes. *Proc Natl Acad Sci USA* 105:17526–17531
81. Donini M, Lico C, Baschieri S et al (2005) Production of an engineered killer peptide in *Nicotiana benthamiana* by using a Potato virus X expression system. *Appl Environ Microbiol* 71:6360–6367
82. Scholl D, Adhya S, Merrill C (2005) *Escherichia coli* K1's capsule is a barrier to bacteriophage T7. *Appl Environ Microbiol* 71:4872–4874
83. Leiman PG, Battisti AJ, Bowman VD et al (2007) The structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide capsules and evolution of new host specificities. *J Mol Biol* 371:836–849